The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study
designed to collect real-world safety and clinical outcomes in approximately 4,200 patients
receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual
antiplatelet therapy (DAPT) drug regimen.
This study will also contribute patient data to an FDA-requested and industry-sponsored
research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT
Study).
Details
Lead Sponsor:
Boston Scientific Corporation
Collaborators:
Daiichi Sankyo Inc. Daiichi Sankyo, Inc. Eli Lilly and Company